Our History

  • 1901-1930

    In the Beginning...

    Established in Jerusalem in 1901, the company known today as Teva starts out as a small wholesale drug business that distributes imported medications.

  • 1901

    A small wholesale drug business is established in Jerusalem by Chaim Salomon, Moshe Levin and Yitschak Elstein. The business is named S.L.E after its founders.
    Original 1901 Pharmacy
  • 1930 - 1940

    A New Pharmaceutical Industry is Founded

    Conditions are ripe for establishing a local pharmaceutical industry. New manufacturing plants are founded and quickly gain momentum. During World War II, these plants are the sole source of pharmaceutical supplies for the local market, neighboring countries and the British Army stationed in the Middle East.

  • 1935

    Salomon, Levin and Elstein open a small pharmaceutical plant called Assia (Aramaic for doctor) in Petah Tikva. Other plants founded at this time include Zori (Hebrew for health) in Tel Aviv and Teva established by Dr. Gunter Friedlander in Jerusalem.
    1935
  • 1940 - 1960

    Expansion of the Local Drug Market

    With the founding of the State of Israel, the local drug market expands rapidly. Established pharmaceutical manufacturing companies grow, including Teva. While most are privately owned, Teva begins trading on the Tel Aviv Stock Exchange in 1951.

  • 1948

    The State of Israel is founded, bringing massive immigration and rapid growth of the local drug market.
    1948
  • 1951

    Teva begins trading on TASE (Tel Aviv Stock Exchange) as the Teva Middle East Pharmaceutical Chemical Works Company Ltd.

    1951
  • 1960 - 1980

    Consolidation of the Local Pharmaceutical Industry

    A period of consolidation in the Israeli pharmaceutical industry beginning in the 1960s culminates with the 1976 union of Teva, Assia, and Zori to create Israel’s largest drugmaker, Teva Pharmaceutical Industries Ltd. Teva takes its first step abroad into Europe.

  • 1964

    Fiscal merger of Assia and Zori, marking a period of rapid growth.
    1964
  • 1968

    Assia-Zori acquires a controlling stake in Teva.
    1968
  • 1971

    Chemical plant established in Petah Tikva, Israel called Assia Chemical Industries Ltd. This plant would later become Teva’s API (Active Pharmaceutical Ingredients) division.
    1971
  • 1972

    Formation of Biological Laboratories Teva Ltd. in Israel
    1972
  • 1972/74

    Compulsory license granted authorizing Teva to produce patented medicines, starting with SmithKline’s antibiotic Penibrin®. Cooperation begins with global pharmaceutical companies.
    1972/74
  • 1976

    Eli Hurvitz formally merges Assia, Zori and Teva to form Teva Pharmaceutical Industries Ltd., Israel's largest healthcare company, and becomes its CEO.
    1976
  • 1976

    Teva purchases 50% of Israeli yeast and alcohol fermentation business Paca Ltd.
  • 1977

    Acquisition of Orphahell in the Netherlands. This API plant is Teva’s first step into Europe, and the start of a chain of international acquisitions.
  • 1979

    Teva establishes corporate offices in Petah Tikva, Israel. They remain there to this day.
    1979
  • 1980-1990

    Going International - Worldwide Expansion

    Teva expands internationally, capitalizing on the passing of the Hatch-Waxman Act to enter the US market in the generics sector. Teva begins trading on NASDAQ, marking the start of a period of robust growth.

  • 1980

    Acquisition of leading Israeli drug manufacturer Ikapharm and 50% of chemical manufacturer Plantex Ltd. from Koor Industries.
    1980
  • 1980

    Following acquisition of assets from Dr. Nissan Preminger, Teva establishes Promedico to market imported products.
  • 1982

    FDA approval received for Teva’s Kfar Saba manufacturing facility.
    1982
  • 1982

    Teva shares are registered for trading on NASDAQ.
  • 1984

    Teva expands its activity in the promising field of medical devices by acquiring a 50% interest in Migada, an Israeli manufacturer of disposable medical equipment.
    1984
  • 1984

    US Hatch-Waxman Act is passed, enabling Teva’s entry into generic medicines in the 1990s.
    1984
  • 1985

    Teva expands its US market share through a 50-50 joint venture with W.R. Grace to form TAG Pharmaceuticals. The joint company acquires Lemmon in Sellersville, PA, facilitating Teva’s entry into the US market.
    1985
  • 1985

    Teva sells its stake in Promedico.
  • 1987

    Teva begins trading on NASDAQ, raising $25.5 million through the sale of American Depositary Receipts (ADRs).
    1987
  • 1987

    Teva acquires the rights to Copaxone® for the treatment of Multiple Sclerosis (MS) from Yeda, the commercial arm of Israel’s Weizmann Institute.
    1987
  • 1988

    Teva acquires Abic, the second largest pharmaceutical company in Israel.
    1988
  • 1989

    Teva expands its activities in the field of medical devices by acquiring the Baxter-owned Israeli company Travenol which is merged with Migada Ltd. to become Teva Medical
  • 1989

    Acquisition of the remaining 50% of Israeli API producer Plantex Ltd.
    1989
  • 1989

    Teva agrees to joint development of Azilect® for the treatment of Parkinson’s disease with the Technion - Israel institute of Technology.
    1989
  • 1990 - 2000

    Extending a Strong Multinational Presence

    Teva’s first major new drug, Copaxone® for the treatment of Multiple Sclerosis (MS), is approved by the FDA. Teva invests in a series of acquisitions that extend its global reach in the US and Europe. The company assumes leadership of the US generics sector.

  • 1992

    Teva purchases W.R Grace’s 50% share of TAG Pharmaceuticals and becomes full owner. Together with Lemmon, this creates Teva Pharmaceutical USA Inc.
    1992
  • 1992

    Teva completes acquisition of the remaining 50% of Migada Ltd.
  • 1992

    Acquisition of GRYPharm - Germany
    1992
  • 1993

    Acquisition of Prosintex - Italy
  • 1994

    Teva opens its flagship Teva-Tech API production facility at Ramat Hovav in Israel’s Negev desert.
  • 1995

    Acquisition of Biogal - Hungary, and ICI - Italy
    1995
  • 1996

    Acquisition of Biocraft – US
  • 1996

    Acquisition of APS/Berk in the UK marks Teva’s first entry into a major Western European market.
    1996
  • 1996

    Teva launches Copaxone® in the US. Copaxone® is marketed and distributed through Teva Marion Partners, a joint venture with Marion Merrell Dow (today Aventis).
    1996
  • 1997

    Acquisition of Pharbil – Netherlands
  • 1997

    Exclusive Marketing Agreement with Biovail for sustained release products.
  • 1998

    Acquisition of Pharmachemie Group - Netherlands
    1998
  • 1999

    Acquisition of Copley Pharmaceuticals Inc. – USA

     

     

     

     

     

     

     

     

     

     

     

     

     

  • 2000 - 2010

    A Leader in Global Markets

    Teva continues to invest in major acquisitions of Canadian, US and EU pharmaceutical companies with subsidiaries in Latin America and elsewhere. Teva becomes the largest generic pharmaceutical company in North America, and strengthens its worldwide presence while broadening its pipeline and product offerings.

  • 2000

    Acquisition of Novopharm Ltd., the second largest producer of generics in Canada, and its Hungarian subsidiary Human. Teva becomes the largest generic pharmaceutical company in North America.
    2000
  • 2001

    Teva gains full ownership of Teva Marion Partners, renamed Teva Neuroscience, and continues to market innovative products including Copaxone® in North America
  • 2001

    Copaxone® receives European Union approval in 2001. Teva begins marketing Copaxone® in Europe in cooperation with Aventis Pharma.
  • 2002

    Eli Hurvitz is appointed Teva’s Chairman of the Board. 
    Photo: Moshe Shai.
    2002
  • 2002

    Israel Makov is appointed Teva's President and CEO.
  • 2002

    Acquisition of Bayer Classics (now Teva Classics) in France, including the Teva Santé manufacturing plant.
    2002
  • 2002

    Acquisition of the Honeywell Pharmaceutical Fine Chemicals plant in northern Italy, renamed Teva PFC, adds to the range of Teva's worldwide API products.
  • 2003

    Acquisition of Regent Drugs Limited in India (renamed Teva API India Ltd.), which joins Teva’s API division.
    2003
  • 2004

    Acquisition of Sicor Inc. and its subsidiaries, bringing together Teva's successful oral dose generic drugs franchise with Sicor's leading generic injectable business, API and biogenerics capabilities.
  • 2004

    Acquisition of Dorom S.r.l. - Italy
  • 2005

    Acquisition of Medika AG – Switzerland
  • 2005

    Azilect®, Teva's innovative drug for the treatment of Parkinson’s disease, is approved for marketing in Israel and the EU.
    2005
  • 2006

    Acquisition of IVAX Corporation in the US strengthens Teva’s worldwide presence through subsidiaries in Europe, Latin America and the Far East. The acquisition brings Teva a rich pipeline of generic and proprietary products in the complementary areas of respiratory, CNS, and oncology.
  • 2006

    FDA approves Azilect® for marketing in the US.
  • 2007

    Shlomo Yanai is appointed Teva's President and CEO.
  • 2007

    Acquisition of Med Ilac – Turkey
    2007
  • 2008

    Acquisition of CoGenesys, a division of Human Genome Sciences – US
  • 2008

    Acquisition of Bentley Pharmaceuticals – Spain
  • 2008

    Acquisition of Barr Pharmaceuticals in the US, including subsidiary PLIVA in Europe, enhances Teva’s leadership position in the US and key global markets, and strengthens Teva's portfolio and pipeline.
    2008
  • 2008

    Joint venture with Japan-based Kowa Company, Ltd. establishes Teva-KOWA Pharma and positions Teva to supply generic pharmaceutical products to the Japanese market.
  • 2009

    Teva-KOWA Pharma acquires a controlling interest in Taisho Pharmaceutical Industries, further expanding Teva-KOWA's operations in Japan.
    2009
  • 2010

    Acquisition of German ratiopharm significantly increases Teva's market share in Europe, harnessing ratiopharm's excellent foundation for biosimilars, branded generics and tenders.

     

     

     

     

     

     

     

     

     

     

     

     

     

  • 2010 - Today

    The World's Largest Medicine Cabinet
    Teva provides medicines to 200 million people around the world every day.
    Teva has one of the most competitive operational networks in the industry, with sales in approximately 100 global markets and a portfolio of 16,000 products, spanning generics, specialty and OTC.

  • 2011

    Acquisition of Theramex, European-based women's health business, brings Teva a broad Women's Health and gynecology portfolio, and a unique innovative pipeline.
    2011
  • 2011

    Acquisition of Corporacion Infarmasa, a top ten pharmaceutical company in Peru, from The Rohatyn Group and Altra Investments.
  • 2011

    Acquisition of Taiyo, the third largest generics manufacturer in Japan, provides Teva with an expanded portfolio and a strong presence in the Japanese pharmaceutical market.
    2011
  • 2011

    Teva-KOWA Pharma completes acquisition of Taisho Pharmaceutical Industries, enhancing Teva’s activity in Japan and strengthening Teva's position in the fast-growing Japanese generics market.
  • 2011

    Acquisition of Cephalon and its global subsidiaries strengthens Teva’s diversification in the areas of CNS, oncology, respiratory and pain while providing a leadership position in branded and specialty pharmaceuticals.
  • 2011

    Establishment of PGT Healthcare. This Teva and Procter & Gamble joint venture expands Teva’s reach through a growing global OTC business.
    2011
  • 2012

    Dr. Jeremy Levin is appointed Teva's President and CEO.
  • 2012

    Teva begins trading on the NYSE (New York Stock Exchange).
    2012
  • 2012

    Teva acquires development rights for Huntexil® for the treatment of Huntington’s disease from Denmark-based Neurosearch A/S. This transaction expands Teva’s CNS development pipeline.
  • 2012

    Development and global licensing agreement for XEN402 with Canadian Xenon Pharmaceuticals Inc. This transaction strengthens Teva’s CNS pipeline with novel treatments for pain-related disorders.
  • 2012

    Joint venture with Handok provides Teva with entrance into the South Korean pharmaceutical market.
    2012
  • 2013

    Acquisition of MicroDose in the US expands Teva’s respiratory pipeline.
  • 2013

    Collaboration between PGT Healthcare and Swisse Wellness integrates both companies’ core strengths, enabling expansion of the Swisse brand of premium VMS products into new countries and the creation of a global megabrand
  • 2014

    Erez Vigodman is appointed Teva's President and CEO.
    2014
  • 2014

    Acquisition of NuPathe Inc. in the US.

  • 2014

    Acquisition of Labrys Biologics Inc. in the US opens the door for Teva to a strong and novel migraine prevention and treatment franchise within its CNS portfolio. 
    2014
  • 2015

    In February 2015, Teva entered into an exclusive license agreement with Eagle for Bendeka™ to strengthen its Treanda® franchise for the treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin’s lymphoma.

  • 2015

    In May 2015, Teva acquired Auspex, in a deal expected to strengthen Teva's core central nervous system franchise with SD-809 (deutetrabenazine), developed to treat several movement disorders.

    2015
  • 2015

    During 2015, Teva acquired stakes in Gecko Health Innovations, Inc., Immuneering Corporation and Microchips Biotech, Inc.

  • 2016

    In March 2016, Teva acquired Rimsa in Mexico.

    2016
  • 2016

    In April 2016, Teva established a business venture with Takeda, Japan's largest pharmaceutical company. The business venture seeks to leverage Takeda’s leading brand reputation and strong distribution presence in Japan with Teva’s expertise in supply chain, operational network, infrastructure and R&D, ultimately serving millions of patients in the growing generic market of Japan.

    2016
  • 2016

    In August 2016, Teva acquired Allergan plc’s worldwide generic pharmaceuticals business, Actavis Generics, significantly expanding Teva’s generics product portfolio, R&D capabilities, product pipeline and global operational network. The acquisition strongly reinforces Teva’s strategy, accelerates the creation of its new business model and opens a new set of possibilities for the company in generics.

  • 2016

    In September 2016, Teva and Regeneron entered into a collaboration agreement to develop and commercialize Regeneron’s pain medication product, Fasinumab.

  • 2016

    In October 2016, Teva and Celltrion entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar products in the US and Canada.

    2016
  • 2016

    In October 2016, Teva acquired Anda, a leading distributor of generic pharmaceuticals in the US. This strategic move enables Teva to improve capabilities and flexibility in order to provide access to more patients throughout the US.

  • 2017

    Kåre Schultz appointed as Teva's President & CEO

    2017